Longeveron (LGVN) Reports Q4 Loss of $0.20/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Longeveron (LGVN) Reports Q4 Loss of $0.20/sh

Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

March 11, 2022 8:00 AM EST

Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimers Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1)

Lomecel-B for HLHS Granted Rare Pediatric Disease and Orphan Drug Designation by the US FDA

Japanese Phase 2 Aging Frailty Trial Expected to Initiate in First Half of 2022

Multiple Clinical Data Publications Expected in 2022

- Conference Call Today at 8:30 a.m. EST -

MIAMI, March 11, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:... More